In approximately 5–22% of EGFR-mutant NSCLC cases resistant to EGFR TKIs, MET amplification drives resistance by maintaining downstream ERK1/2 and AKT signalling [68]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.